Study Identifies Senolytics as Enhancers of Chemotherapy Anti-metastatic Activity in Prostate Cancer

A preclinical study shows that senolytic therapies targeting upregulated BCL2 and IAP pathways can eliminate chemotherapy-induced senescent cells, remodeling the SASP to activate CD8+ T cells and suppress metastatic progression in prostate cancer models.

Researchers at the University of Massachusetts Chan Medical School evaluated various cancer therapeutics and found that chemotherapies (such as docetaxel) and targeted Aurora kinase and CDK inhibitors induce robust cellular senescence in prostate cancer models.

The study demonstrated that docetaxel-induced senescent cells secrete a senescence-associated secretory phenotype (SASP) containing extracellular matrix (ECM) remodeling factors that facilitate cancer cell dissemination and metastasis.

By applying senolytic therapies targeting the pro-survival BCL2 and IAP pathways, which are upregulated in these senescent cells, the researchers successfully cleared the senescent tumor cells.

This senolytic clearance remodeled the inflammatory SASP, which in turn repolarized myeloid phenotypes and potentiated CD8+ T cell activation, leading to suppressed tumor metastasis and reduced growth in syngeneic mouse models.

Therapy-induced senescence is a common cytostatic outcome of oncology drugs, but the dual nature of the SASP can paradoxically drive metastasis and cause immune suppression in certain contexts.

Demonstrating that senolytic intervention can resolve these negative SASP effects and restore anti-tumor immunity provides a logical framework for senolytic-chemotherapy combination regimens in advanced cancers.

The discovery highlights BCL2 and IAP pathways as functional therapeutic vulnerabilities specifically induced by frontline chemotherapeutic agents.

This finding expands the addressable therapeutic indications for senolytic platforms, transitioning cellular senescence clearance technologies from purely age-related indications into oncology combinations.

The data could catalyze strategic partnerships between developers of Bcl-2 family inhibitors or senescent cell clearance platforms and larger biopharmaceutical companies seeking to improve standard-of-care chemotherapy regimens like docetaxel.

Translational preclinical models and potential early-phase clinical trials exploring combination therapies of BCL2 and IAP inhibitors alongside docetaxel in advanced, metastatic prostate cancer patients.